Ticagrelor-d7

CAT: 0804-HY-10064S-01Size: 500 µgDry Ice: NoHazardous: No
CAT#:0804-HY-10064S-01Size:500 µg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].
CAS Number
[1265911-55-4]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Isotope-Labeled Compounds; P2Y Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Others
Applications
Cancer-programmed cell death
Field of Research
Cardiovascular Disease; Cancer
Purity
97.59
Solubility
10 mM in DMSO
Smiles
N(C1=C2C(N(N=N2)[C@@]3(C[C@H](OCCO)[C@@H](O)[C@H]3O)[H])=NC(SC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])=N1)[C@H]4[C@@](C4)(C5=CC(F)=C(F)C=C5)[H]
Molecular Formula
C23H21D7F2N6O4S
Molecular Weight
529.61
Precautions
H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[3]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[4]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
P2Y12 Receptor

Popular Products